New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 14, 2018 - Supernus Pharmaceuticals announced the FDA approval of Oxtellar XR (oxcarbazepine), for the treatment of partial-onset seizures in patients 6 years of age and older.
Download PDF
Return to publications
